Solid Biosciences (SLDB) grants director 77,500 stock options at $6.61

Rhea-AI Filing Summary

Solid Biosciences Inc. director Lynne Marie Sullivan received a grant of director stock options covering 77,500 shares of common stock. The options have an exercise price of $6.61 per share and expire on June 10, 2036.

The grant was made on June 10, 2026 and vests in full on the earlier of the one-year anniversary of the grant date or immediately prior to the company’s next annual meeting of stockholders after the grant. Any unvested portion will vest automatically upon specified change in control events. This is a compensation-related award rather than an open-market purchase.

Insights

Equity compensation analyst

Director receives routine stock option grant as board compensation.

Director Lynne Marie Sullivan was granted options on 77,500 shares of Solid Biosciences Inc. common stock at an exercise price of $6.61 per share, expiring on June 10, 2036. The Form 4 classifies this as a grant/award acquisition, not a market trade.

The award vests fully on the earlier of the one-year anniversary of the June 10, 2026 grant date or immediately before the next annual meeting of stockholders, with full acceleration upon specified change in control events. This pattern is typical for director compensation and, standing alone, is generally viewed as routine rather than a directional signal.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sullivan Lynne Marie

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	77,500	$0.00	--

Holdings After Transaction: Director Stock Option (Right to Buy) — 77,500 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 77,500 options Exercise price: $6.61 per share Expiration date: June 10, 2036 +2 more

5 metrics

Options granted 77,500 options Director stock option grant on June 10, 2026

Exercise price $6.61 per share Director stock option exercise price

Expiration date June 10, 2036 Option term for director grant

Shares underlying options 77,500 shares Common stock underlying the director stock option

Vesting trigger Earlier of 1 year or next annual meeting Vesting schedule for June 10, 2026 grant

Key Terms

Director Stock Option (Right to Buy), grant/award acquisition, change in control events, annual meeting of stockholders

4 terms

Director Stock Option (Right to Buy) financial

"security_title: "Director Stock Option (Right to Buy)""

grant/award acquisition financial

"transaction_action: "grant/award acquisition""

change in control events financial

"will vest automatically as to 100% ... upon specified change in control events"

annual meeting of stockholders financial

"immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sullivan Lynne Marie

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MASSACHUSETTS 02129

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$6.61	06/10/2026		A		77,500		(1)	06/10/2036	Common Stock	77,500	$0.00	77,500	D

Explanation of Responses:

1. This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

	/s/ by Kimberly Cornwell as attorney-in-fact for Lynne Marie Sullivan	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Solid Biosciences (SLDB) director Lynne Marie Sullivan receive in this Form 4?

Lynne Marie Sullivan received a grant of director stock options for 77,500 shares of Solid Biosciences common stock. The options are a compensation-related award, not a market purchase, and give her the right to buy shares at a fixed exercise price.

What is the exercise price of the new SLDB director stock options?

The granted options have an exercise price of $6.61 per share. This means Lynne Marie Sullivan can purchase Solid Biosciences common stock at $6.61 if she exercises the options after they vest and before they expire.

When do Lynne Marie Sullivan’s Solid Biosciences options vest?

The options vest in full on the earlier of one year after the June 10, 2026 grant date or immediately before Solid Biosciences’ next annual meeting of stockholders after that date. This creates a relatively short, service-based vesting period for the director.

How long are the Solid Biosciences director stock options outstanding?

The options expire on June 10, 2036, giving a 10-year term from the grant date. Lynne Marie Sullivan must exercise vested options before this expiration date to acquire Solid Biosciences common shares at the fixed $6.61 exercise price.

Do the SLDB director options accelerate on a change in control?

Yes. Any unvested portion of the option will vest automatically upon specified change in control events. This means that if a qualifying transaction occurs, Lynne Marie Sullivan’s remaining unvested options become fully exercisable under the described conditions.